platoseedplatoseed
Robotic human cell manufacturing
Mytos builds robots for manufacturing human cells. Operators input stem cells, and our platform turns them into specific cells such as neurons and heart cells over multiple weeks. Last year, patients were cured of Parkinson’s, vision loss, and Type 1 diabetes using stem-cell derived cells. We need 1000x the global capacity to produce these cells, and treat millions of patients. But today these Regenerative Medicines are produced by hand, meaning they’re too expensive and don’t scale. Mytos has fully automated production of these cells, making it scalable. We have our first manufacturing deal - neurons for treating Parkinson’s - and we’re in conversations with majority of the other top players.
Mytos provides automated, scalable manufacturing for regenerative medicine using its iDEM automation technology. The company positions itself as an automated CDMO that enables low-cost, high-throughput production with end-to-end support for process development and regulatory needs.
Mytos offers an automated CDMO platform powered by iDEM automation technology that automates all unit operations in cell culture, preserves biology, and enables rapid scaling with reduced labor and footprint. The system uses the same 2D T-flask format as manual culture to allow rapid porting of protocols to closed automation, avoiding a single point of failure unlike large robotic arms. Mytos provides end-to-end manufacturing services from Process Analytical Development to Regulatory Support, with no suite fees or device purchases required, delivering up to 50% lower batch costs and faster tech transfers.
Who it’s for: Clinical-stage regenerative medicine companies working on indications across brain, eye, bone, and related tissues seeking scalable, cost-efficient automated manufacturing.
Has multiple published partnerships and manufacturing collaborations; mentions ongoing hiring and global site expansion plans
CEO and Co-Founder of Mytos. I'm a mixture between a scientist and an engineer, having solved challenges both using physics/chemistry, as well as through building hardware and software. I aspire to operate at the interface of science and engineering, where low level science translates into meaningful products.
Formerly “HackScience”, “Cytera CellWorks” · why startups rename →
Democratizing gene therapy by reinventing its manufacturing and…
Enabling next generation medicines. A comprehensive platform and…
